Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high110.00 10/08/16
52 week low60.00 31/03/17
52 week change -1.50 (-1.78%)
4 week volume374,512 02/07/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
01/08/2014
Presenter: Dr. Alastair Smith
07/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Dealing and Issue of Equity

Manchester ShareSoc Growth Company Seminar

ShareSoc Growth Company Seminar

Issue of Equity

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

2 Biotech's Licence Affimers for Research Use

Miscellaneous medium priority announcements

Avacta to be granted patent in China

Avacta Group has announced that the principal patent protecting the Affimer technology had been accepted for grant in C...

Moderna releases Phase I trial data for mRNA technology

Avacta Group has confirmed that Moderna has disclosed Phase I trial data for its mRNA technology. It says this is the firs...

Hardman Research: De-risking Moderna's partnership

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
24/05/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
08/05/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
12/04/2017
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...

Latest discussion posts More

  • Re: Affimer Technology

    Amrik Basran http://www.ophthalmology-futures.com/singapore-2017-videos/ mol
    23-Jul-2017
    mol42
  • Trading statement?

    There was a positive trading statement issued last year on 1st August. Since then: Positive results RNS 22nd September 16 First Affimer pre-clinical 1st November ...
    19-Jul-2017
    TheDrewster
  • ShareSoc Evening

    bit of an update from this blog of evening Next up was the final presentation of the evening and it was delivered by Dr. Alastair Smith, CEO of Avacta Life Sciences. Avacta ...
    16-Jul-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.17%
ROCKHOPPER15%
ROYAL BANK SCOT11%
BARCLAYS11%
AFC ENERGY11%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT